Cahill Prevails on Behalf of Jazz Pharmaceuticals and GW Pharma in the Federal Court of Appeals
Cahill and its Chair of Life Sciences Patent Litigation, Gerald Flattmann, Jr., scored a major win for clients Jazz Pharmaceuticals and GW Pharma in the Federal Circuit Court of Appeals on Monday, April 24. The Court of Appeal’s unanimous opinion affirmed the decision of the Western District of Texas in favor of our clients. That decision had found that based on the legal meaning of the scientific terms in Canopy Growth Corp.’s patent relating to the production of cannabidiol (“CBD”) from cannabis, our clients’ method of making its groundbreaking product Epidiolex did not infringe. Epidiolex is the first ever FDA approved oral cannabinoid and is used to treat intractable and rare infant and childhood epilepsies. Gerald argued the appeal on behalf of our clients on April 3 and the Federal Circuit’s judgment affirming the District Court’s judgment of non-infringement issued yesterday.
Please click below to read the published opinion.
United States Court of Appeals for the Federal Circuit Opinion (pdf | 308.51 KB )